Cart
sales@molnova.com
tiquizium
CAS No. 149755-23-7
tiquizium( —— )
Catalog No. M28946 CAS No. 149755-23-7
Tiquizium has effective Antimuscarinic effect, and causes significant bronchodilation in patients with chronic obstructive pulmonary disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 151 | In Stock |
|
| 5MG | 149 | In Stock |
|
| 10MG | 220 | In Stock |
|
| 25MG | 337 | In Stock |
|
| 50MG | 462 | In Stock |
|
| 100MG | 619 | In Stock |
|
| 200MG | 835 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Nametiquizium
-
NoteResearch use only, not for human use.
-
Brief DescriptionTiquizium has effective Antimuscarinic effect, and causes significant bronchodilation in patients with chronic obstructive pulmonary disease.
-
DescriptionTiquizium has effective Antimuscarinic effect, and causes significant bronchodilation in patients with chronic obstructive pulmonary disease.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetAChR
-
RecptorEAAT2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number149755-23-7
-
Formula Weight330.53
-
Molecular FormulaC19H24NS2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC[N+](CCCC1)(C2)[C@H]1CCC2=C(c1cccs1)c1cccs1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Kortagere S, et al. Identification of Novel Allosteric Modulators of Glutamate Transporter EAAT2. ACS Chem Neurosci. 2018 Mar 21;9(3):522-534.
molnova catalog
related products
-
M4 mAChR agonist-1?
M4 mAChR agonist-1 is an effective agonist of M4 mAChR (EC50 >10 μM).
-
9-CP-Ade Mesylate
9-CP-Ade Mesylate (9 CP Ade Mesylate) is a cell-permeable, stable and non-competitive inhibitor of adenylate cyclase.
-
Xanomeline
Xanomeline (LY-246708) is a functionally selective M1/M4 activator used in the study of neurological disorders such as schizophrenia and has shown promising treatment in preclinical trials.
